Cross-Sectional Survey of Factors Contributing to COVID-19 Testing Hesitancy Among US Adults at Risk of Severe Outcomes from COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE
    • Publication Information:
      Publication: 2014- : [Auckland] Adis
      Original Publication: [London] : Springer Healthcare
    • Abstract:
      Introduction: The United States Centers for Disease Control and Prevention (CDC) advises testing individuals for COVID-19 after exposure or if they display symptoms. However, a deeper understanding of demographic factors associated with testing hesitancy is necessary.
      Methods: A US nationwide cross-sectional survey of adults with risk factors for developing severe COVID-19 ("high-risk" individuals) was conducted from August 18-September 5, 2023. Objectives included characterizing demographics and attitudes associated with COVID-19 testing. Inverse propensity weighting was used to weight the data to accurately reflect the high-risk adult US population as reflected in IQVIA medical claims data. We describe here the weighted results modeled to characterize demographic factors driving hesitancy.
      Results: In the weighted sample of 5019 respondents at high risk for severe COVID-19, 58.2% were female, 37.8% were ≥ 65 years old, 77.1% were White, and 13.9% had a postgraduate degree. Overall, 67% were Non-testers (who indicated that they were unlikely or unsure of their likelihood of being tested within the next 6 months); these respondents were significantly more likely than Testers (who indicated a higher probability of testing within 6 months) to be female (60.2 vs. 54.1%; odds ratio [OR] [95% confidence interval (CI)], 1.3 [1.1‒1.4]), aged ≥ 65 years old (41.5 vs. 30.3%; OR [95% CI] compared with ages 18‒34 years, 0.6 [0.5‒0.7]), White (82.1 vs. 66.8%; OR [95% CI], 1.4 [1.1‒1.8]), and to identify as politically conservative (40.9 vs. 18.1%; OR [95% CI], 2.6 [2.3‒2.9]). In contrast, Testers were significantly more likely than Non-testers to have previous experience with COVID-19 testing, infection, or vaccination; greater knowledge regarding COVID-19 and testing; greater healthcare engagement; and concerns about COVID-19.
      Conclusions: Older, female, White, rural-dwelling, and politically conservative high-risk adults are the most likely individuals to experience COVID-19 testing hesitancy. Understanding these demographic factors will help guide strategies to improve US testing rates.
      (© 2024. The Author(s).)
    • References:
      BMJ Nutr Prev Health. 2022 Jan 19;5(1):10-18. (PMID: 35814718)
      PNAS Nexus. 2022 Jul 04;1(3):pgac071. (PMID: 35860600)
      JAMA. 2022 Dec 13;328(22):2203-2204. (PMID: 36511918)
      JAMA Health Forum. 2024 Jan 5;5(1):e235044. (PMID: 38277170)
      Am J Prev Med. 2023 May;64(5):761-764. (PMID: 37085247)
      Res Sq. 2021 Jun 25;:. (PMID: 34189524)
      Stat Med. 2010 Feb 10;29(3):337-46. (PMID: 19960510)
      MMWR Morb Mortal Wkly Rep. 2023 May 05;72(18):488-492. (PMID: 37141156)
      Int J Environ Res Public Health. 2022 Jun 21;19(13):. (PMID: 35805227)
      JMIR Infodemiology. 2021 Aug 27;1(1):e26895. (PMID: 34541460)
      Eur J Health Econ. 2022 Jun;23(4):617-625. (PMID: 35169950)
      Vaccine X. 2022 Oct 17;12:100227. (PMID: 36275889)
      J R Stat Soc Ser A Stat Soc. 2018 Oct;181(4):1193-1209. (PMID: 30555215)
      PLoS One. 2016 Oct 21;11(10):e0164541. (PMID: 27768704)
      JAMA. 2024 Feb 20;331(7):548-551. (PMID: 38294771)
      J Infect. 2020 Aug;81(2):e16-e25. (PMID: 32335169)
      MMWR Morb Mortal Wkly Rep. 2022 Dec 02;71(48):1531-1537. (PMID: 36454693)
      ILAR J. 2002;43(4):207-13. (PMID: 12391396)
      Vaccines (Basel). 2021 Mar 22;9(3):. (PMID: 33810131)
      Virology. 2022 Nov;576:105-110. (PMID: 36206606)
      Int J Environ Res Public Health. 2021 Feb 25;18(5):. (PMID: 33668958)
      JAMA Netw Open. 2022 Nov 1;5(11):e2241144. (PMID: 36350654)
      Sci Rep. 2021 Nov 4;11(1):21844. (PMID: 34737319)
      Lancet. 2022 Apr 16;399(10334):1463-1464. (PMID: 35344735)
      N Engl J Med. 2022 Apr 14;386(15):1397-1408. (PMID: 35172054)
      Public Health. 2022 Nov;212:14-21. (PMID: 36182746)
      Nat Commun. 2021 Jan 4;12(1):29. (PMID: 33397962)
      N Engl J Med. 2023 Feb 2;388(5):385-387. (PMID: 36724378)
      BMC Public Health. 2022 Apr 14;22(1):750. (PMID: 35422031)
      Pers Individ Dif. 2021 Sep;179:110892. (PMID: 34866723)
      Health Res Policy Syst. 2023 Jan 25;21(1):11. (PMID: 36698202)
    • Contributed Indexing:
      Keywords: COVID-19; Risk factors; SARS-CoV-2; Survey; Testing
    • Publication Date:
      Date Created: 20240613 Latest Revision: 20240705
    • Publication Date:
      20240705
    • Accession Number:
      PMC11219613
    • Accession Number:
      10.1007/s40121-024-01001-5
    • Accession Number:
      38869840